Drug Trial Radar · NCT07541287
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
May 19, 2026
Primary completion
Jan 2029
Study completion Apr 2029
Sponsor
- Lead sponsor
- Jade Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient population.
Conditions
- IgA Nephropathy
Interventions
JADE101Drug
JADE101 is supplied as sterile solution to be administered by SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (safety and tolerability)Time frame: Day 1 through 100 weeks
Locations
22 sites in 5 countries. Site status is shown where the registry gives one.
Jade Clinical Site
Chula Vista, California · Recruiting
Jade Clinical Site
Arvada, Colorado · Recruiting
Jade Clinical Site
Denver, Colorado · Recruiting
Jade Clinical Site
Orlando, Florida · Recruiting
Jade Clinical Site
Pembroke Pines, Florida · Recruiting
Jade Clinical Site
Houston, Texas · Recruiting
Jade Clinical Site
Concord, New South Wales, Australia · Recruiting
Jade Clinical Site
Liverpool, New South Wales, Australia · Recruiting
Jade Clinical Site
Parkville, Victoria, Australia · Recruiting
Jade Clinical Site
Christchurch, New Zealand · Recruiting
Jade Clinical Site
Anyang-si, South Korea · Recruiting
Jade Clinical Site
Seongnam-si, South Korea · Recruiting
Jade Clinical Site
Seoul, South Korea · Recruiting
Jade Clinical Site
Seoul, South Korea · Recruiting
Jade Clinical Site
Seoul, South Korea · Recruiting
Jade Clinical Site
Suwon, South Korea · Recruiting
Jade Clinical Site
Kaohsiung City, Kaohsiung, Taiwan · Recruiting
Jade Clinical Site
Taichung, Taichung, Taiwan · Recruiting
Jade Clinical Site
New Taipei City, Taipei, Taiwan · Recruiting
Jade Clinical Site
Taipei, Taipei, Taiwan · Recruiting
Jade Clinical Site
Taipei City, Taipei, Taiwan · Recruiting
Jade Clinical Site
Taiyuan, Taoyuan, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.